Abstract 445P
Background
Nasopharyngeal cancer (NPC) is notably prevalent in Southeast Asia, including Hong Kong. The survival rate of NPC patients has improved over the past decade. However, the emergence of various late radiation side effects during survivorship remains a concern. While the clinician-reported incidence of symptoms has been reported, a comprehensive assessment of self-reported symptoms is still lacking. This study aims to examine the subjective symptom burden, quality of life, and unmet needs among local NPC survivors.
Methods
A single-centre cross-sectional survey was conducted at a local public hospital, including 200 NPC survivors who had completed radiation therapy (RT) with or without chemotherapy for three to 120 months. We employed the Chinese version of three questionnaires: M. D. Anderson Symptom Inventory - Head & Neck Module (MDASI-HN), Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN), and Cancer Survivors’ Unmet Needs Measure (CaSUN).
Results
Survivors experienced, on average, more than four moderate to severe symptoms (Mean [M] ± SD = 4.84±4.99), with no association found with post-RT time (p = 0.443). The top five severe symptoms were dry mouth (M±SD = 5.47±2.90), mucus problem (M±SD = 4.27±3.17), dysphagia (M±SD = 3.38±3.03), teeth/gum problems (M±SD = 2.98±3.17), and poor memory (M±SD = 2.94±2.63). The mean scores of the top five symptoms were used to represent the symptom burden, which was negatively associated with the physical (F(1,198) = 139.783, p < 0.001, R2 = 0.414), emotional (F(2,197) = 38.303, p < 0.001, R2 = 0.280), additional concerns (F(1,198) = 85.993, p < 0.001, R2 = 0.303) subscales, and the total scores (F(2,197) = 33.083, p < 0.001, R2 = 0.251) of the FACT-HN. The unmet need for symptom management by CaSUN was positively associated with symptom burden (OR = 1.379, 95% CI [1.185, 1.604], p < 0.001), while negatively associated with post-RT time (OR = 0.981, 95% CI [0.972, 0.991], p < 0.001).
Conclusions
NPC survivors suffer from symptoms irrespective of the time elapsed post-RT. The observed varying unmet need for symptom management necessitates further exploration into supportive care for cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract